Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Aug;46(6):1412-1419.
doi: 10.1002/jpen.2309. Epub 2022 Jan 5.

High-dose supplementation of selenium in left ventricular assist device implant surgery: A double-blinded, randomized controlled pilot trial

Elena Laaf  1   2 , Carina Benstoem  2   3 , Rolf Rossaint  1 , Sebastian Wendt  1   2 , Christina Fitzner  1   2 , Ajay Moza  4 , Rashad Zayat  4 , Aileen Hill  1   2   3 , Daren K Heyland  5   6 , Lutz Schomburg  7 , Andreas Goetzenich  8 , Christian Stoppe  1   9
Affiliations
Randomized Controlled Trial

High-dose supplementation of selenium in left ventricular assist device implant surgery: A double-blinded, randomized controlled pilot trial

Elena Laaf et al. JPEN J Parenter Enteral Nutr. 2022 Aug.

Abstract

Background: Systemic inflammation and oxidative stress remain the main causes of complications in patients with heart failure receiving a left ventricular assist device (LVAD). Selenoproteins are a cornerstone of antioxidant defense mechanisms for improving inflammatory conditions.

Methods: In a monocentric, double-blinded pilot trial patients scheduled for LVAD implantation were randomized to receive 300 mcg of selenium orally the evening before surgery, followed by a high-dose of intravenous selenium supplementation (3000 mcg after anesthesia induction, 1000 mcg upon intensive care unit [ICU] admission, and 1000 mcg daily in the ICU for a maximum of 14 days) or placebo. The main outcomes were feasibility and effectiveness in restoring serum selenium concentrations.

Results: Twenty patients were included in the analysis. The average duration of study intervention was 12.6 days (7-14), with 97.7% dose compliance. No patient received open-label selenium. The supplementation strategy was effective in compensating low serum selenium concentrations (before surgery: control, 63.5 ± 11.9 mcg/L vs intervention, 65.8 ± 16.5 mcg/L; ICU admission: control, 49.0 ± 9.8 mcg/L vs intervention, 144.2 ± 45.4 mcg/L). Serum selenium concentrations in the intervention group were significantly higher during the observation period (baseline: mean of placebo (MoP), 63.1 vs mean of selenium (MoS), 64.0; ICU admission: MoP, 49.0 vs MoS, 144.6; day 1-13: MoP, 43.6-48.5 vs MoS, 100.4-131.0).

Conclusion: Selenium supplementation in patients receiving LVAD implantation is feasible and effective to compensate a selenium deficiency.

Keywords: LVAD; inflammation; left ventricular assist device; selenium; trace elements.

PubMed Disclaimer

References

REFERENCES

    1. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873-1884.
    1. Puehler T, Ensminger S, Schoenbrodt M, et al. Mechanical circulatory support devices as destination therapy-current evidence. Ann Cardiothorac Surg. 2014;3(5):513-524.
    1. Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37(2):357-361.
    1. Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203-230.
    1. Mondal NK, Sorensen EN, Pham SM, et al. Systemic inflammatory response syndrome in end-stage heart failure patients following continuous-flow left ventricular assist device implantation: differences in plasma redox status and leukocyte activation. Artif Organs. 2016;40(5):434-443.

Publication types

LinkOut - more resources